Overview

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Status:
Not yet recruiting
Trial end date:
2023-07-21
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen